Prime HCD

We are excited to announce that Idaira Rodríguez Santana will be in attendance at this year’s #HSG2024. Please get in touch to arrange a meeting. See you there! #huntingtons #rarediseases #PrimeHCD #Prime

Join us for an insightful panel discussion at the World Orphan Drug Congress Europe 2024 in Barcelona! Sue O'Leary, Executive Vice President, Evidence & Access, Prime will be moderating the discussion on ‘Optimising Value Demonstration and Evidence in Rare Disease’.    🗓️ Date: Thursday, 24th October 🕒 Time: 11:55 AM 📍 Location: Theatre 6, WODC This session will explore how access bodies like NICE assess rare disease evidence during health technology assessments. The discussion will also delve into innovative methods beyond clinical trials that pharma companies can leverage to demonstrate product value. Additionally, we will discuss how pharmaceutical companies can internally organize their processes to ensure efficient and effective evidence planning while adapting to changing roles and responsibilities. Meet Our Esteemed Panelists: Sue O'Leary - Moderator, Executive Vice President, Evidence & Access, Prime Jennifer Quinn, Head of Global Value and Access, Debiopharm International Stuart Mealing, Associate Director (HEOR), York Health Economics Consortium & NICE HST Committee Member Simon S.,(Simon Shohet) PhD, Vice President, International Market Access and HEOR, Amicus Therapeutics Mukesh Sharma, PhD, Head of Early Pipeline and Business Development, Alexion Pharmaceuticals Don’t miss this opportunity to gain valuable insights and network with industry leaders in the rare disease space. We look forward to seeing you there! #RareDisease #Pharma #ValueDemonstration #WODC2024

Meet with Prime’s expert integrated strategy team to explore optimising evidence for your rare disease assets! At Prime we understand the importance of ensuring that the right evidence is captured early in development to drive investment and secure patient access through the multiple payer assessment bodies. As patient-focused outcomes and analytics is key in rare disease, it is essential that teams break down silos and are strategically aligned across functions, starting in early development. Our integrated team of leaders Peter, Tom and Sue bring together their expertise in strategic planning, outcomes analytics and market access and look forward to discussing your challenges at WODC. Please visit us at booth 61 or contact Sue O'Leary, Peter Agathangelou or Tom Burke on the WODC app! #WODC #RareDiseases #OrphanDrugs #HealthcareInnovation #Networking #Prime #Impact

We are thrilled to announce the team attending the World Orphan Drug Congress 2024! 📅 Save the date: 22-25 October 2024📍 Location: Barcelona Join us for an unparalleled experience as we explore the latest strategies, advocacy efforts, and partnerships shaping the orphan drug industry. Let’s come together to drive impactful change in the rare disease space! If you'd like to meet, please contact Sue O'Leary at sue.oleary@primeglobalpeople.com or visit us at Booth 61! We hope to see you there! At Prime, we are dedicated to making a positive change by partnering with the world's leading names in healthcare and technology to deliver meaningful solutions. For more information on our services, visit our website: www.primeglobalpeople.com Sue O'Leary Peter Agathangelou George Miles Tom Burke Rachael Kershaw Charlie Weston #WODC2024 #RareDiseases #OrphanDrugs #HealthInnovation #Prime

We are happy to share our poster that will be presented at #WMS2024 today at 15:45- 16:45 CEST Poster No. 336P Location: Forum Hall #DMD #WMS #PrimeHCD #Prime

On World Mental Health Day, let’s all come together to talk about mental health and show everyone that mental health matters. Talking about our mental health can help us cope better with life’s ups and downs. So, on World Mental Health Day and beyond it, why not check in with your friends, family, peers, or colleagues?  World Mental Health Day is celebrated every year on 10 October. This year’s theme set by the World Federation of Mental Health is workplace mental health. The theme highlights the importance of addressing mental health and wellbeing in the workplace, for the benefit of people, organisations, and communities. 

We're excited to announce that we'll be attending the World Orphan Drug Congress Europe 2024 in Barcelona from 22-25 October! As the largest and most established meeting for orphan drugs and rare diseases, this event is a hub of innovation and progress. Please visit us at booth 61 to explore how our expert services in health economics, real-world evidence, market access, and value communications can help you unlock the full potential of your asset development. From cell & gene therapy to market access and real-world evidence, we’re here to support you at every stage and demonstrate value every step of the way! Let’s achieve your strategic goals together! We hope to see you there! #WorldOrphanDrugCongress #WODC #RareDiseases #OrphanDrugs #MarketAccess #HealthEconomics #CellAndGeneTherapy #ValueCommunications

Today is PFIC Awareness Day. Every year on 5th October we recognise, share and support our PFIC community. For more information click the link https://lnkd.in/eA2cd4_V

We are pleased to share our October article on HIV. Beyond the cure: Assessing the long-term gains of Curative Therapies. A review of our modelling approach to the long term health and cost outcomes of HIV. https://lnkd.in/ez7nD6p8 #HIV #curativetherapies #PrimeHCD #Prime

Today we celebrate International Gaucher day 🎉 Gaucher disease is a rare inherited (genetic), enzyme deficiency disorder. Symptoms range from mild to severe and can appear at any time, from infancy to old age. They may include anaemia, tiredness, easy bruising and a tendency to bleed. People with Gaucher diease lack sufficient activity of an enzyme called glucocerebrosidase. For more information - https://lnkd.in/dRA8iEM9 #gaucherdisease #raredisease #PrimeHCD #Prime